+148.6%
TE vs MRNA
+511.3%
-362.6%
-69.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.3% | -2.2% | +3.6% | +1.4% |
| 7D | -4.0% | +5.5% | -9.4% | -4.2% |
| 30D | -15.9% | +158.7% | -174.6% | -25.7% |
| 3M | -60.5% | +182.1% | -242.7% | -67.1% |
| 6M | -35.2% | +151.8% | -187.0% | -43.9% |
| YTD | -31.1% | +393.6% | -424.7% | -57.2% |
| 1Y | +148.6% | +499.5% | -350.8% | +41.4% |
| All | +148.6% | +511.3% | -362.6% | +41.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling